PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

February 5, 2016

The following overview highlights the critical role adequate and effective intellectual property rights protections and fair and equitable market access play in enabling biopharmaceutical innovators in the United States to research, develop and deliver valuable new medicines for patients who need them around the world. It describes serious and pressing intellectual property and market access barriers abroad and recommends steps the Office of the U.S. Trade Representative (USTR) and other federal agencies can take to address and resolve these barriers. The attached country profiles provide additional details and examples.

Spotlight

Daewoong Pharmaceuticals

Establish in 1945, Daewoong Pharmaceuticals Co., Ltd. is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both the domestic and international markets. Through our strong M&S divisions, Daewoong has the largest prescription drug sales in the South Korean market. Presently, we commercialize 10 blockbuster products. In addition, we have built a strong internal core competency for new drug development and have expanded regional and global collaborations with international partners. To reach our goal to become a global health care company, Daewoong has expanded international operations establishing branches offices throughout Asia and research centers in the US, China, and India. Currently, Daewoong is constructing a new manufacturing facility under cGMP guidelines to meet the needs of our global partners.

OTHER WHITEPAPERS
news image

Transforming Patient Journey in Clinical Trials

whitePaper | April 7, 2022

Year after year, the Life Sciences industry expands at a breakneck pace, with pharmaceutical development leading the way.

Read More
news image

2022 Global Life Sciences Outlook

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

Read More
news image

How Cellular is Enabling the Digital Supply Chain

whitePaper | January 12, 2020

Supply chains grow more and more complex every day. In response, manufacturers and shippers have been eagerly exploring digital tools that provide actionable insight into the location and condition of in-transit goods. Although there are many technology options when it comes to building a digital supply chain, one type of solution stands out as the most reliable and cost-effective: cellular.

Read More
news image

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Read More
news image

BUILDING RESILIENT SUPPLY CHAINS REVITALIZING AMERICAN MANUFACTURING AND FOSTERING BROAD-BASED GROWTH

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

Read More
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More

Spotlight

Daewoong Pharmaceuticals

Establish in 1945, Daewoong Pharmaceuticals Co., Ltd. is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both the domestic and international markets. Through our strong M&S divisions, Daewoong has the largest prescription drug sales in the South Korean market. Presently, we commercialize 10 blockbuster products. In addition, we have built a strong internal core competency for new drug development and have expanded regional and global collaborations with international partners. To reach our goal to become a global health care company, Daewoong has expanded international operations establishing branches offices throughout Asia and research centers in the US, China, and India. Currently, Daewoong is constructing a new manufacturing facility under cGMP guidelines to meet the needs of our global partners.

Events